Boiron (BOI.PA) Stock Price

Boiron Price

Euronext·CLOSED
27.40EUR+0.10 (+0.37 %)
Market closed

Over the last 19 years Boiron grew revenue by 1.2% annually, reaching 501.11 M EUR. Earnings per share have grown at 7.5% per year over the last 19 years. For Boiron, the net margin of 6.5% is broadly stable versus 6.3% a few years ago. At today's price the dividend yield works out to roughly 4.38%. The payout ratio is around 65% of earnings. The dividend has grown at 6.4% per year over the past 19 years. The consensus 12-month price target for Boiron is 40.43 EUR, about 47.6% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 30% above its 52-week low.

Boiron stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Boiron over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Boiron stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Boiron's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Boiron Stock Price History
DateBoiron Price
7/31/202627.40 EUR
7/30/202627.30 EUR
7/29/202627.40 EUR
7/28/202627.10 EUR
7/27/202627.20 EUR
7/24/202627.30 EUR
7/23/202627.00 EUR
7/22/202626.80 EUR
7/21/202626.80 EUR
7/20/202627.00 EUR
7/17/202626.80 EUR
7/16/202627.00 EUR
7/15/202627.50 EUR
7/14/202627.50 EUR
7/13/202627.50 EUR
7/10/202627.50 EUR
7/9/202627.30 EUR
7/8/202626.70 EUR
7/7/202626.60 EUR
7/6/202627.30 EUR
7/3/202627.80 EUR
7/2/202627.60 EUR
7/1/202627.60 EUR
6/30/202627.70 EUR
6/29/202628.00 EUR
6/26/202628.20 EUR
6/25/202628.00 EUR
6/24/202627.80 EUR
6/23/202628.10 EUR
6/22/202627.80 EUR
6/19/202627.50 EUR
6/18/202627.60 EUR
6/17/202627.40 EUR
6/16/202627.80 EUR
6/15/202628.00 EUR
6/12/202628.15 EUR
6/11/202628.20 EUR
6/10/202628.60 EUR
6/9/202628.70 EUR
6/8/202628.40 EUR
6/5/202628.90 EUR
6/4/202628.30 EUR
6/3/202627.10 EUR
6/2/202628.70 EUR
6/1/202628.10 EUR
5/29/202628.30 EUR
5/28/202628.00 EUR
5/27/202628.00 EUR
5/26/202627.70 EUR
5/25/202627.40 EUR
5/22/202627.50 EUR
5/21/202627.40 EUR
5/20/202626.50 EUR
5/19/202626.80 EUR
5/18/202627.80 EUR
5/15/202628.70 EUR
5/14/202629.00 EUR
5/13/202628.50 EUR
5/12/202627.90 EUR
5/11/202627.90 EUR
5/8/202627.50 EUR
5/7/202627.90 EUR
5/6/202626.70 EUR
5/5/202627.10 EUR
5/4/202628.00 EUR
4/30/202627.40 EUR
4/29/202626.20 EUR
4/28/202626.50 EUR
4/27/202625.60 EUR
4/24/202625.40 EUR
4/23/202625.70 EUR
4/22/202625.80 EUR
4/21/202626.00 EUR
4/20/202625.20 EUR
4/17/202625.20 EUR
4/16/202625.40 EUR
4/15/202625.80 EUR
4/14/202626.00 EUR
4/13/202626.50 EUR
4/10/202626.90 EUR
4/9/202626.90 EUR
4/8/202627.40 EUR
4/7/202628.00 EUR
4/2/202627.93 EUR
3/27/202626.15 EUR
3/25/202625.60 EUR
3/24/202625.65 EUR
3/23/202625.55 EUR
3/20/202626.00 EUR
3/19/202625.25 EUR
3/18/202626.00 EUR
3/17/202626.10 EUR
3/16/202626.10 EUR
3/13/202626.00 EUR
3/12/202626.15 EUR
3/11/202626.25 EUR
3/10/202626.30 EUR
3/9/202626.05 EUR
3/6/202626.95 EUR
3/5/202626.34 EUR
2/26/202626.85 EUR
2/25/202627.35 EUR
2/24/202627.00 EUR
2/23/202627.19 EUR
2/20/202627.35 EUR
2/19/202627.25 EUR
2/18/202627.55 EUR
2/17/202627.35 EUR
2/16/202628.50 EUR
2/13/202629.85 EUR
2/12/202628.65 EUR
2/11/202629.85 EUR
2/10/202629.35 EUR
2/9/202629.50 EUR
2/6/202629.50 EUR
2/5/202629.50 EUR
2/4/202629.50 EUR
2/3/202629.94 EUR
2/2/202629.80 EUR
1/30/202629.66 EUR
1/29/202630.00 EUR
1/28/202630.35 EUR
1/27/202629.90 EUR
1/26/202630.00 EUR
1/23/202630.60 EUR
1/22/202630.65 EUR
1/21/202630.35 EUR
1/20/202630.25 EUR
1/19/202630.15 EUR
1/16/202630.25 EUR
1/15/202630.20 EUR
1/14/202630.25 EUR
1/13/202630.30 EUR
1/12/202630.25 EUR
1/9/202630.04 EUR
1/8/202630.11 EUR
1/7/202630.00 EUR
1/6/202629.63 EUR
1/5/202629.95 EUR
1/2/202630.10 EUR
12/31/202529.90 EUR
12/30/202529.90 EUR
12/29/202530.00 EUR
12/24/202530.40 EUR
12/23/202530.29 EUR
12/22/202530.25 EUR
12/19/202529.88 EUR
12/18/202530.25 EUR
12/17/202530.00 EUR
12/16/202529.75 EUR
12/15/202529.80 EUR
12/12/202529.80 EUR
12/11/202529.62 EUR
12/10/202530.05 EUR
12/9/202530.50 EUR
12/8/202530.60 EUR
12/5/202530.67 EUR
12/4/202529.13 EUR
12/3/202529.16 EUR
12/2/202529.05 EUR
12/1/202529.00 EUR
11/28/202528.48 EUR
11/27/202528.08 EUR
11/26/202528.10 EUR
11/25/202527.44 EUR
11/24/202527.15 EUR
11/21/202526.60 EUR
11/20/202526.35 EUR
11/19/202526.25 EUR
11/18/202526.85 EUR
11/17/202526.95 EUR
11/14/202525.95 EUR
11/13/202525.90 EUR
11/12/202526.50 EUR
11/11/202526.85 EUR
11/10/202526.25 EUR
11/7/202527.15 EUR
11/6/202527.90 EUR
11/5/202527.68 EUR
11/4/202527.60 EUR
11/3/202528.00 EUR
10/31/202528.10 EUR
10/30/202528.20 EUR
10/29/202528.08 EUR
10/28/202528.00 EUR
10/27/202527.75 EUR
10/24/202528.00 EUR
10/23/202527.20 EUR
10/22/202527.80 EUR
10/21/202527.60 EUR
10/20/202526.90 EUR
10/17/202526.90 EUR
10/16/202527.70 EUR
10/15/202526.75 EUR
10/14/202526.65 EUR
10/13/202527.40 EUR
10/10/202527.45 EUR
10/9/202527.85 EUR
10/8/202527.17 EUR
10/7/202526.45 EUR
10/6/202526.45 EUR
10/3/202527.11 EUR
10/2/202527.23 EUR
10/1/202527.43 EUR
9/30/202527.65 EUR
9/29/202528.50 EUR
9/26/202529.15 EUR
9/25/202529.20 EUR
9/24/202528.90 EUR
9/23/202528.40 EUR
9/22/202527.55 EUR
9/19/202526.55 EUR
9/18/202524.85 EUR
9/17/202524.50 EUR
9/16/202524.20 EUR
9/15/202524.38 EUR
9/12/202523.62 EUR
9/11/202524.13 EUR
9/10/202523.60 EUR
9/9/202523.56 EUR
9/8/202523.26 EUR
9/5/202522.17 EUR
9/4/202521.90 EUR
9/3/202521.68 EUR
9/2/202521.55 EUR
9/1/202521.28 EUR
8/29/202521.05 EUR
8/28/202521.20 EUR
8/27/202521.30 EUR
8/26/202521.40 EUR
8/25/202521.70 EUR
8/22/202522.60 EUR
8/21/202521.95 EUR
8/20/202521.35 EUR
8/19/202521.07 EUR
8/18/202521.04 EUR
8/15/202521.15 EUR
8/14/202521.10 EUR
8/13/202521.00 EUR
8/12/202521.15 EUR
8/11/202521.17 EUR
8/8/202521.00 EUR
8/7/202521.31 EUR
8/6/202521.46 EUR
8/5/202521.45 EUR
Access this data via the Eulerpool API
Get Free API Key

Boiron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
513.58 M EUR
38.19 M EUR
26.21 M EUR
Jan 1, 2021
455.20 M EUR
37.92 M EUR
28.56 M EUR
Jan 1, 2022
534.24 M EUR
56.70 M EUR
44.67 M EUR
Jan 1, 2023
493.25 M EUR
42.29 M EUR
35.83 M EUR
Jan 1, 2024
487.56 M EUR
15.74 M EUR
11.34 M EUR
Jan 1, 2025
501.11 M EUR
36.60 M EUR
32.64 M EUR
Jan 1, 2026 (e)
0.00 EUR
42.87 M EUR
35.69 M EUR
Jan 1, 2027 (e)
540.57 M EUR
44.37 M EUR
36.97 M EUR

Boiron Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 3:33 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
566.00617.00609.00607.00614.00617.00604.00557.00513.00455.00534.00493.00487.00501.00–540.00
8.229.01-1.30-0.331.150.49-2.11-7.78-7.90-11.3117.36-7.68-1.222.87––
77.5679.9080.7980.4079.6479.2577.6577.0276.8071.8770.9772.6273.5172.85–72.85
439.00493.00492.00488.00489.00489.00469.00429.00394.00327.00379.00358.00358.00365.00365.00393.41
81.00146.00146.00135.00133.00130.00108.0072.0038.0037.0056.0042.0015.0036.0042.0044.00
14.3123.6623.9722.2421.6621.0717.8812.937.418.1310.498.523.087.19–8.15
49.0082.0089.0073.0077.0078.0057.0040.0026.0028.0044.0035.0011.0032.0035.0036.00
16.6767.358.54-17.985.481.30-26.92-29.82-35.007.6957.14-20.45-68.57190.919.382.86
0.700.901.201.501.501.601.601.451.050.950.9512.561.351.201.231.27
–28.5733.3325.00–6.67–-9.38-27.59-9.52–1,222.11-89.25-11.112.503.25
21.2819.4219.1118.4318.4318.4317.5317.5117.5117.5217.3817.3617.3617.6417.6417.64
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Boiron generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Boiron retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Boiron's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Boiron has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Boiron's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Boiron stock margins

The Boiron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Boiron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Boiron.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
76.86 %
7.44 %
5.10 %
Jan 1, 2021
71.97 %
8.33 %
6.27 %
Jan 1, 2022
71.08 %
10.61 %
8.36 %
Jan 1, 2023
72.60 %
8.57 %
7.26 %
Jan 1, 2024
73.58 %
3.23 %
2.33 %
Jan 1, 2025
72.98 %
7.30 %
6.51 %
Jan 1, 2026 (e)
72.98 %
- %
- %
Jan 1, 2027 (e)
72.98 %
8.21 %
6.84 %

Boiron Stock Revenue, EBIT, Earnings per Share

The Boiron earnings per share therefore indicates how much revenue Boiron has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
29.32 EUR
2.18 EUR
1.50 EUR
Jan 1, 2021
25.99 EUR
2.16 EUR
1.63 EUR
Jan 1, 2022
30.73 EUR
3.26 EUR
2.57 EUR
Jan 1, 2023
28.41 EUR
2.44 EUR
2.06 EUR
Jan 1, 2024
28.08 EUR
0.91 EUR
0.65 EUR
Jan 1, 2025
28.40 EUR
2.07 EUR
1.85 EUR
Jan 1, 2026 (e)
0.00 EUR
2.43 EUR
2.06 EUR
Jan 1, 2027 (e)
31.13 EUR
2.51 EUR
2.13 EUR

Boiron business model & stock analysis

Boiron SA is a French company specializing in the production of homeopathic medicines. It was founded in 1932 by the brothers Jean and Henri Boiron and has its headquarters in Lyon, France. Boiron SA is now a global leader in the production of medicines based on natural ingredients.

Boiron SWOT Analysis

Strengths

1. Established Brand: Boiron SA is a well-known and respected brand in the pharmaceutical industry.

2. Strong Research & Development: The company invests heavily in R&D, resulting in a strong pipeline of innovative products.

3. Global Presence: Boiron SA has a presence in multiple countries, allowing for diversification and access to different markets.

Weaknesses

1. Limited Product Range: Boiron SA primarily focuses on homeopathic medicines, which may limit market potential.

2. Dependence on Regulatory Environment: Changes in regulations or government policies can impact the company's operations and sales.

3. Vulnerability to Counterfeit Products: As a popular brand, Boiron SA faces the risk of counterfeit products, which can harm its reputation.

Opportunities

1. Growing Demand for Natural Remedies: Increasing consumer interest in natural and holistic healthcare presents an opportunity for Boiron SA to expand its market share.

2. Emerging Markets: Boiron SA can explore expansion in emerging markets where there is a growing demand for healthcare products.

3. Online Sales Channels: The company can leverage e-commerce platforms to reach a larger customer base and enhance its sales.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share.

2. Patents and Intellectual Property: Boiron SA's patents and intellectual property rights may be infringed upon by competitors.

3. Shifting Consumer Preferences: Changes in consumer preferences or a lack of trust in homeopathic medicines can impact the demand for Boiron SA's products.

Boiron Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Boiron historical P/E ratio, EBIT multiple, and P/S ratio

Boiron annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Boiron shares outstanding

The number of shares of Boiron was 17.64 M in 2025. This indicates how many shares Boiron is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
17.51 M Stocks
Jan 1, 2021
17.52 M Stocks
Jan 1, 2022
17.38 M Stocks
Jan 1, 2023
17.36 M Stocks
Jan 1, 2024
17.36 M Stocks
Jan 1, 2025
17.64 M Stocks
Jan 1, 2026 (e)
17.64 M Stocks
Jan 1, 2027 (e)
17.64 M Stocks

Boiron stock splits

In Boiron's history, there have been no stock splits.

Boiron Dividend History

36 years of dividend payments

YearAnnual DividendYoY ChangePayments
20251.20EUR↓ 11.1%1×
Jun 3, 20251.20EUR↓ 11.1%1/1
20241.35EUR↓ 89.3%1×
202312.56EUR↑ 1,222.1%3×
20220.95EUR 0.0%1×
20210.95EUR↓ 9.5%1×
20201.05EUR↓ 27.6%1×
20191.45EUR↓ 9.4%1×
20181.60EUR 0.0%1×
20171.60EUR↑ 6.7%1×
20161.50EUR 0.0%1×

Boiron dividend history and estimates

In 2025, Boiron paid a dividend amounting to 1.20 EUR. Dividend means that Boiron distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2020
1.05 EUR
0.00 EUR
0.00 EUR
Jan 1, 2021
0.95 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022
0.95 EUR
0.00 EUR
0.00 EUR
Jan 1, 2023
12.56 EUR
0.00 EUR
10.36 EUR
Jan 1, 2024
1.35 EUR
0.00 EUR
0.00 EUR
Jan 1, 2025
1.20 EUR
0.00 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
1.23 EUR
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
1.27 EUR
0.00 EUR

Boiron dividend payout ratio

In 2025, Boiron had a payout ratio of 64.86%. The payout ratio indicates the percentage of the company's profits that Boiron distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
70.16 %
Jan 1, 2021
58.27 %
Jan 1, 2022
36.97 %
Jan 1, 2023
608.68 %
Jan 1, 2024
206.77 %
Jan 1, 2025
64.86 %
Jan 1, 2026 (e)
59.96 %
Jan 1, 2027 (e)
59.44 %

Current Boiron forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.10 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
40.43
Last Price
27.40
Currency
EUR
12M Return Potential
47.56 %
LTM Return
0 %

Boiron Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/31/2009-EUR-226.34 MEUR-2009 Q2
3/11/2009-EUR-241.67 MEUR-2008 Q4
8/29/2008-EUR-218.63 MEUR-2008 Q2

EESG©

Eulerpool ESG Scorecard© for the Boiron stock

70/100
99
Environment
95
Social
17
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions6,420
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees67.9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Boiron shareholder structure

% Name
79.81384%
Boiron Family
Boiron Family
1.05071%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.79934%
HMG Finance S.A.
HMG Finance S.A.
0.42186%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.31169%
Sycomore Asset Management
Sycomore Asset Management
0.25117%
PEH Wertpapier AG
PEH Wertpapier AG

Boiron Beneficial Ownership Filings (SEC 13D/G)

Free Float
16.5%
Float Shares
-
Shares Outstanding
-

Boiron Executives and Management Board

16 members · avg. age 54 · 38 % women

TB

Mr. Thierry Boiron (63)

Chief Executive Officer · since 1996

270,443.00 EUR

Management

JB

Mr. Jean-Christophe Michel Bayssat (61)

Deputy Chief Executive Officer, Chief Pharmacist, Pharmaceutical Development Director

30,000.00 EUR
FR

Mr. Fabrice Rey

Head of Investor Relations · since 2022

–

Board of Directors

SM

Mr. Sylvain Mossaz (48)

Non-Executive Director - Employees Representative

95,712.00 EUR
JH

Mr. Jean-francois Henaux (53)

Non-Executive Director - Employees Representative

88,994.00 EUR
GW

Mr. Gregory Walter (46)

Non-Executive Director - Representative of Shareholder Employees

62,883.00 EUR
PB

Mr. Philippe Brun (63)

Non-Executive Independent Director

38,851.00 EUR
AB

Ms. Anne Borfiga (52)

Non-Executive Independent Director

34,569.00 EUR
SC

Mrs. Stephanie Chesnot (52)

Non-Executive Director

31,770.00 EUR

Frequently asked questions about Boiron

The business model of Boiron SA is focused on the development, production, and distribution of homeopathic products. As a leading pharmaceutical company, Boiron specializes in providing natural and alternative medicines to customers worldwide. The company's core values include a commitment to research, innovation, and quality. Boiron's extensive product portfolio ranges from single homeopathic medicines to complex remedies, ensuring a wide variety of options for various health conditions. With a strong emphasis on patient well-being, Boiron SA aims to promote the benefits of homeopathy and improve the quality of life for individuals seeking alternative healthcare solutions.

Boiron SA is primarily active in the healthcare industry.

The main competitors of Boiron SA in the market are Hyland's, Nelsons, and Weleda.

Boiron SA is a renowned global pharmaceutical company based in France. Founded in 1932 by Jean and Henri Boiron, the company specializes in manufacturing and distributing homeopathic medicines. With years of dedication and expertise, Boiron SA has become a trusted name in the pharmaceutical industry. The company's success can be attributed to its commitment to quality and innovation. Boiron SA continues to expand its product range and has a strong presence in over 50 countries worldwide. With a rich history and unwavering dedication to homeopathy, Boiron SA remains a leading player in the global healthcare market.

Boiron SA, a prominent stock company, has achieved several significant milestones. Over its history, the company has made noteworthy accomplishments in the pharmaceutical industry. Boiron SA has successfully expanded its presence across various international markets, enabling global recognition and revenue growth. Additionally, the company has consistently delivered cutting-edge healthcare solutions and innovative products, establishing itself as a leader in the industry. Boiron SA's commitment to research and development has resulted in breakthrough treatments and improved patient outcomes. With a strong dedication to excellence, Boiron SA continues to drive advancements in the pharmaceutical sector, solidifying its position as a trusted and successful stock investment opportunity.

Boiron SA is primarily present in several countries and regions across the globe. The company has a significant presence in Europe, with a strong focus on its home market in France. Boiron SA also operates in various other European countries, including Germany, Italy, Spain, and the United Kingdom. Additionally, the company has established a presence in North America, particularly in the United States and Canada. Boiron SA's presence extends further to countries in Asia, such as China and Japan. With a global reach, Boiron SA serves customers and markets in multiple countries and regions, solidifying its position as a leading company in the pharmaceutical industry.

Boiron SA represents a set of core values and a strong corporate philosophy. With a focus on customer satisfaction and healthcare excellence, Boiron SA aims to provide high-quality and effective homeopathic medicines. The company is committed to promoting natural health solutions and sustainability, ensuring the well-being of individuals and the environment. Boiron SA's dedication to research, innovation, and expertise drives their mission of improving people's lives through safe and trusted homeopathic remedies. Known for their commitment to ethics and responsibility, Boiron SA strives to be a leader in the global homeopathy market, bringing holistic wellness to individuals worldwide.

Analysts currently set an average price target of 40.43 EUR for the Boiron stock (median: 40.43 EUR), implying +47.6 % versus the latest price. The consensus is based on 5 analyst ratings.

Boiron Analyst Price Targets 2026

5 analysts currently rate the Boiron stock: 4 recommend buying, 1 holding and 0 selling.

Boiron Analyst Price Targets 2026

The Boiron share (BOI.PA) is listed on 7 stock exchanges, including: Frankfurt (BON.F), München (BON.MU), Düsseldorf (BON.DU), London (0DTF.L), London (0DTF.L), Paris (BOI.PA).

Boiron SA is a leading manufacturer of homeopathic medicines, founded in 1932 and based in Lyon, France. The company consists of three business areas - healthcare, sustainability, and research & development.

The revenue cannot currently be calculated for Boiron.

The expected profit of Boiron is 35.69 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Boiron is currently 13.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Boiron stock.

The P/S cannot be calculated for Boiron currently.

The Eulerpool Quality Score for Boiron is 2/10.

The ISIN of Boiron is FR0000061129. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Boiron is 873532. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Boiron is BOI.PA. The ticker symbol is used to trade Boiron shares on the stock exchange.

Over the past 12 months, Boiron paid a dividend of 1.20 EUR . This corresponds to a dividend yield of about 4.38 %. For the coming 12 months, Boiron is expected to pay a dividend of 1.27 EUR.

The current dividend yield of Boiron is 4.38 %.

Boiron pays a dividend, distributed in the months of , , , .

Boiron paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 1.27 EUR are expected. This corresponds to a dividend yield of 4.62 %.

Boiron is assigned to the 'Health' sector.

To receive the latest dividend of Boiron from amounting to 1.2 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Boiron distributed 1.35 EUR as dividends.

The dividends of Boiron are distributed in EUR.

All fundamentals and in-depth analysis of Boiron

Our stock analysis for Boiron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boiron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Boiron Stock
Boiron Revenue→
Boiron Stock
Boiron Net Income→
Boiron Stock
Boiron P/E→
Boiron Stock
Boiron P/S→
Boiron Stock
Boiron EBIT→
Boiron Stock
Boiron Dividend→
Boiron Stock
Boiron Directors Dealings→
Boiron Stock
Boiron Stocks→
Boiron Stock
Boiron Market capitalization→
Boiron Stock
Boiron Debt→
Boiron Stock
Boiron Liabilities→
Boiron Stock
Boiron Equity→
Boiron Stock
Boiron AAQS→
Boiron Stock
Boiron Employees→
Boiron Stock
Boiron ROE→
Boiron Stock
Boiron ROA→
Boiron Stock
Boiron ROCE→
Boiron Stock
Boiron News→
Boiron Stock
Boiron Analyst Price Targets→

Health Stocks

Boji Medical Technology CoBoditech MedBolt BiotherapeuticsBNC Korea CoBone BiologicsBNB PlusBonesupport HoldingBMLBonraybio CoBMC Medical CoBonus BiogroupBluelineaAll Stocks A–Z →